AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02957240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury.
Study NCT02957240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Representation Techniques
Description: Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist.
Study NCT06562829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Description: Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
Study NCT06562829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different timing of lidocaine injection
Description: Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
Study NCT06638684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
Study NCT06638684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
Study NCT02853136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine
Study NCT01193270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water in volume equal to that of the comparator drug
Study NCT03254979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle prescription
Description: 3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits.
Study NCT03254979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle prescription
Description: 3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits.
Study NCT01180621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral
Description: 0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
Study NCT01011335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent rAT
Description: 10, 25, 50 or 100 μg
Study NCT01011335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent rLukS-PV
Description: 10, 25, 50 or 100 μg
Study NCT01011335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLukS-PV / rAT
Description: 10, 25 or 50 μg
Study NCT01011335 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with adjuvant
Description: Placebo with adjuvant
Study NCT01011335 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study NCT00282581 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA Smallpox Vaccine
Description: 0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
Study NCT02685696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis O Retractor
Description: A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
Study NCT02685696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Retractor
Description: The traditional self-retaining metal Collins Caesarean Wound Retractor.
Study NCT02824185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)
Description: A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
Study NCT03815240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No dressing
Description: no dressing at sacrum
Study NCT03815240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Sacrum
Description: adhesive sacrum dressing
Study NCT03815240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALLEVYN Life Sacrum
Description: adhesive sacrum dressing
Study NCT03815240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optifoam® Gentle Sacrum
Description: adhesive sacrum dressing
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stoss vitamin D
Description: A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily vitamin D
Description: Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stoss placebo
Description: A single 1.5 mL dose administered on Day 1
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stoss placebo
Description: A single 1.5 mL dose administered on Day 1
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily placebo
Description: A once daily 0.2 mL dose administered from Day 1 to 90
Study NCT03257215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily placebo
Description: A once daily 0.2 mL dose administered from Day 1 to 90
Study NCT03700827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: High-intensity Resistance Training Group
Study NCT03700827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic Interval Training Group
Study NCT01953887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral
Study NCT01953887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study NCT01953887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral
Study NCT03877341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral fusion
Description: Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
Study NCT03877341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior lumbar interbody fusion
Description: Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
Study NCT04889391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Danicopan
Description: Liquid-filled capsules.
Study NCT02096367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Study NCT02096367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinematic gait analysis in lower limb
Study NCT02096367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of static posture
Study NCT02096367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait on treadmill
Description: Treadmill during 2 minutes
Study NCT02096367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle vibration stimulation
Description: Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
Study NCT03160586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stuttering severity instrument-3
Description: To measure of degree of stuttering in child
Study NCT03160586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Child Behavior Checklist for age 4-18
Description: To measure of percent of anxiety in child by ask parents about his or her behaviour
Study NCT02039063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 2 mg/kg
Study NCT02039063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 5 mg/kg
Study NCT02039063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 10 mg/kg
Study NCT02039063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011 15 mg/kg
Study NCT03278509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
Study NCT02853136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - Powder for oral solution (PfOS)
Description: BI 409306 - Powder for oral solution (PfOS)
Study NCT02853136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - film coated tablet
Description: BI 409306 - film coated tablet
Study NCT02167867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lay End Users
Description: Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
Study NCT02167867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Subject Group
Description: Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
Study NCT01980264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Generation Microscopy
Description: Harmonic Generation Microscopy is a nonlinear optical microscopy.
Study NCT03424343 — intervention group
Intervention type: OTHER
Intervention: Questionnaire bundle
Description: Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
Study NCT03424343 — intervention group
Intervention type: OTHER
Intervention: Obtaining information from survivors' medical file
Description: After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
Study NCT05210543 — intervention group
Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients do not receive intervention; observational study
Study NCT03877549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
Study NCT03877549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
Study NCT02331303 — intervention group
Intervention type: OTHER
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
Study NCT02997085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live-Action 360° Video Virtual Reality
Description: 360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
Study NCT02997085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGI 360° Video Virtual Reality
Description: Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
Study NCT03592355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: Clinicians will have a synchronous video visit with their patients.
Study NCT02129972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon videocapsule endoscopy (PillCam colon 2)
Description: This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy.
Study NCT02626884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT03921567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
Study NCT03921567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
Study NCT03921567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride and Ketamine
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
Study NCT03921567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
Study NCT01927913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602
Description: 32, 50 or 75 mg/kg/day BID, capsule
Study NCT01927913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Per approved country specific label
Study NCT06042816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free-opioid anesthesia
Description: Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
Study NCT06042816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid anesthesia
Description: Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
Study NCT01868412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abilar 10% resin salve
Description: The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.